Company intelligence / Profile preview

LMH Biotech

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

LMH Biotech is an early-stage biotechnology company focused on developing novel small molecule therapeutics for oncology and inflammatory diseases. The company's lead research efforts center on the modulation of the Prostaglandin E2 (PGE2) pathway, specifically targeting the EP4 receptor to overcome immune suppression in the tumor microenvironment. By developing highly selective EP4 antagonists, LMH Biotech aims to enhance the efficacy of existing immunotherapies and provide new treatment options for patients with refractory solid tumors. The company is currently advancing its lead candidates through pre-clinical validation and IND-enabling studies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on LMH Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMH Biotech.

Explore the full profile